References
- Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
- Klauschen F, Andreeff M, Keilholz U, et al. The combinatorial complexity of cancer precision medicine. Oncoscience. 2014;1(7):504–509.
- Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368(22):2059–2074.
- Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–510.
- Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681–3687.
- Grunwald MR, Levis MJ. FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia. Semin Hematol. 2015;52(3):193–199.
- Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502–515.
- Tyner JW, Yang WF, Bankhead A 3rd, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73(1):285–296.
- Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416–1429.
- Bennett TA, Montesinos P, Moscardo F, et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014;14(4):305–318.
- Hourigan CS, Karp JE. Personalized therapy for acute myeloid leukemia. Cancer Discov. 2013;3(12):1336–1338.
- Kon Kim T, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol. 2015;52(3):172–183.
- Ghiaur G, Wroblewski M, Loges S. AML and its microenvironment: a molecular conversation. Semin Hematol. 2015;52(3):200–206.
- Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013;10(8):460–471.
- Hourigan CS, McCarthy P, De Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):154–163.
- Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811–822.
- Hokland P, Ommen HB, Mule MP, et al. Advancing the minimal residual disease concept in acute myeloid leukemia. Semin Hematol. 2015;52(3):184–192.
- Marshall G, Blacklock J, Cameron C. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–782.
- Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book. 2015;35:e141–e147.
- Ramos NR, Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695.
- Burnett AK. Treatment of acute myeloid leukemia: are we making progress? ASH Education Program Book. 2012;2012(1):1–6.
- Estey E. Why is progress in acute myeloid leukemia so slow? Semin Hematol. 2015;52(3):243–248.